Third Coast Therapeutics

Third Coast Therapeutics is a biotechnology company focused on developing small molecule inhibitors to treat metastatic cancer. The company's primary focus is on the Snail (SNAI1) protein, a master regulator of the epithelial-mesenchymal transition (EMT) process that allows cancer cells to migrate and colonize other organs. By targeting the protein-protein interactions of Snail, Third Coast aims to prevent or reverse metastasis in various solid tumors, including breast and colon cancers. The technology originated from research at Northwestern University and represents a novel approach to oncology by targeting the spread of cancer rather than just primary tumor growth. Although the company reached the pre-clinical stage, it is currently considered inactive.